OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) saw its stock sink early Monday morning following an update from its Phase 2 Alpine study. The company announced an update following a pre-planned January 23 interim …
In a report released on 12/20/2016 SunTrust increased the stock price target of OncoMed Pharma …
SunTrust Banks
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) traded 241761 shares and was closed at $7.64 per share. …
Shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) have been given a consensus rating of “Buy” by …
Today's Most Active Call & Put Options of the S&P 500 » Nektar Therapeutics (NKTR) saw options trading volume of 9,027 contracts, representing approximately 902,700 underlying shares or approximately 61.8% of NKTR's …
Guest: Bloomberg stocks editor David Wilson on today’s market winners, losers, and Stock of the Day: OncoMed Pharmaceuticals (OMED). producer: Samara Lenga +1-212-617-2984 or slenga@bloomberg.net Running time …
Shares of OncoMed Pharmaceuticals Inc. (OMED) sank into a new 52-week low yesterday, and could be a company to watch at the open. The company’s stock fell to as low as $7.41 yesterday after opening at $7.69. …
OncoMed Pharmaceuticals Inc. stock OMED, -0.65% plunged 37% in pre-market trade Monday, after an independent data safety monitoring board advised "of several findings regarding futility" of a Phase 2 clinical …
The deal pushed the stock of OncoMed (NASDAQ: OMED), an anti-cancer stem cell drug developer, up more than 100 percent by mid-day trading to $29.59 per share — a level unseen since its first week of trading in July. The …
Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in …